Communiqués Vext Science, Inc.

Actions

VEXT

CA9255401064

Installations et services en soins de santé

Temps Différé Canadian Securities Exchange 17:58:44 24/09/2026			Varia. 5j.	Varia. 1 janv.
0,2400 ^CAD	-4,00 %		-4,00 %	-5,88 %

17/09	Vext Science rouvre un dispensaire dans l'Ohio et prolonge l'échéance de ses billets d'acquisition jusqu'en 2029	MT
17/09	Vext Science, Inc. reprend ses activités dans son dispensaire de Jackson, dans l'Ohio	CI

Communiqués

17/09	Vext Announces Reopening of Jackson, Ohio Dispensary and Restructuring of Ohio Seller Notes Ahead of December 2026 Maturity	NE
04/09	Vext Provides Operational Update on Jackson, Ohio Dispensary	NE
20/08	Vext Science : Financial document - (Vext Science Inc FS 2026 Q2 final)	PU
20/08	Vext Science : Financial document - (Vext Science Inc MDA 2026 Q2 final 1)	PU
20/08	Vext Reports Q2 2026 Financial Results; Opens Sixth Ohio Dispensary, Completes Arizona Cultivation Wind-Down; Adjusted EBITDA Grows for Second Consecutive Quarter	NE
12/08	Vext Announces Date for Q2 2026 Financial Results Release	NE
02/06	Vext Opens Sixth Ohio Dispensary in Fairfield	NE
21/05	Vext Reports Q1 2026 Financial Results; Adjusted EBITDA up 73% Sequentially to $3.6 Million as Ohio Platform Scales	NE
15/05	Vext Engages Zuanic & Associates	NE
14/05	Vext Announces Date for Q1 2026 Financial Results Release	NE
29/04	Vext Science : Fourth Quarter 2025 Press Release	PU
29/04	Vext Science : Fourth Quarter 2025 Financial Statements	PU
29/04	Vext Science : Fourth Quarter 2025 MD&A	PU
29/04	Vext Reports Q4 and FY 2025; Fiscal 2025 Revenue up +43% to $51.4M, Operating Cash Flow up +256% to $11.7M as Ohio Retail Scales	NE
21/04	Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results Release	NE
30/03	Vext Science Announces Strategic Optimization of Arizona Operations and Plans for Ohio Cultivation Expansion	NE
03/03	Vext Advances Ohio Expansion with Seventh Retail Location	NE
02/01	Early Warning News Release of Jason T. Nguyen	NE
11/12	Vext Announces Voting Results of Annual General Meeting	NE
20/11	CORRECTION FROM SOURCE: Vext Reports Q3 2025 Financial Results	NE
20/11	Vext Science : Third Quarter 2025 Press Release	PU
20/11	Vext Science : Third Quarter 2025 Financial Statements	PU
20/11	Vext Science : Third Quarter 2025 MD&A	PU
20/11	Vext Reports Q3 2025 Financial Results; Revenue Up 41% Year-over-Year and Operating Cash Flow Year-To-Date Reaches $8.5 Million	NE
11/11	Vext to Announce Financial Results for Q3 2025 on November 20, 2025	NE